Strong Quarterly Performance

Abbott Laboratories has announced a robust start to 2025, with first-quarter revenue climbing 4% to $10.4 billion compared to the previous year. The company's net earnings saw an impressive 8.2% increase, reaching $1.3 billion, while diluted earnings per share (EPS) grew by 8.6% to $0.76.

Leadership's Perspective

"Abbott's diversified business model continues to drive top-tier sales and EPS growth," stated CEO Robert Ford. He emphasized the company's ability to navigate through uncertainties and maintain sustainable growth, thanks to its strategic diversification and execution.

2025 Outlook Reaffirmed

Abbott has reaffirmed its guidance for 2025, projecting organic sales growth between 7.5% and 8.5%. The company also expects an adjusted operating margin of 23.5% to 24.0% of sales and adjusted diluted EPS ranging from $5.05 to $5.25.